The Barricaid® prosthesis is designed to close large defects in the annulus, which often lead to disc reherniation and/or disc collapse following discectomy surgery. The Barricaid® allows surgeons to perform a limited nucleotomy in patients, by offering a secure closure to those presented with a large defect. The Barricaid® track-record spans over 8 years of clinical experience, including one of the largest level I superiority RCTs in spine, where Barricaid® has been compared to the gold standard, discectomy alone.
Australian Biotechnologies Pty Ltd. was founded in 2000 and is located in Sydney, Australia. As a specialist in allograft tissue processing, Australian Biotechnologies delivers optimal solutions for all clinical biologic and allograft requirements, to supply allografts for a wide range of patient needs and surgical procedures.
Oxiplex® from FzioMed acts as a mechanical barrier, preventing excessive epidural fibrosis without affecting normal dural and tissue healing following surgical dissection or disruption. Oxiplex has had no device related adverse events since its introduction in 2002. Oxiplex is a 100% synthetic, highly versatile gel / film for spinal, orthopaedic, gynaecological and aesthetic applications. Spinal applications include discectomies to serve as a temporary mechanical barrier separating opposing tissue surfaces as well as adjunct to posterior lumbar laminectomy, laminotomy or fusion procedures for reducing pain, radiculopathy, lower extremity weakness and severity of postoperative adhesions.